eFFECTOR Therapeutics Inc EFTR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EFTR is a good fit for your portfolio.
News
-
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
-
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
-
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Trading Information
- Previous Close Price
- $1.85
- Day Range
- $1.75–1.87
- 52-Week Range
- $1.60–37.00
- Bid/Ask
- $1.79 / $1.80
- Market Cap
- $6.61 Mil
- Volume/Avg
- 152,631 / 405,329
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 14
- Website
- https://www.effector.com
Comparables
Valuation
|
Metric
|
EFTR
|
CGEM
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.79 | 0.97 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
EFTR
CGEM
EQRX
Financial Strength
|
Metric
|
EFTR
|
CGEM
|
EQRX
|
|---|---|---|---|
Quick Ratio | 0.71 | 16.60 | 18.43 |
Current Ratio | 0.77 | 17.07 | 18.78 |
Interest Coverage | −11.60 | — | — |
Quick Ratio
EFTR
CGEM
EQRX
Profitability
|
Metric
|
EFTR
|
CGEM
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −131.64% | −24.60% | −15.72% |
Return on Equity (Normalized) | — | −25.95% | −16.71% |
Return on Invested Capital (Normalized) | −155.81% | −29.67% | −21.31% |
Return on Assets
EFTR
CGEM
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wjbrtslxb | Mhfw | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bnhtxxz | Pkslc | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qjvbkzhw | Bryzptd | $99.5 Bil | |
MRNA
| Moderna Inc | Nysfkbvfm | Hjsk | $38.8 Bil | |
ARGX
| argenx SE ADR | Shxdvgpb | Mdvbj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lzkqhwjkr | Krxs | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yzxnxztr | Bqvcbg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mprmjcvxg | Pdxdqzt | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fcbyfbzwx | Wrvlkmr | $12.5 Bil | |
INCY
| Incyte Corp | Skdmtqrcs | Frgcrh | $11.6 Bil |